NASDAQ:TNDM Tandem Diabetes Care Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $61.81 +2.62 (+4.43%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$58.75▼$61.8750-Day Range$53.22▼$105.8252-Week Range$52.69▼$155.86Volume477,373 shsAverage Volume741,824 shsMarket Capitalization$3.95 billionP/E Ratio772.72Dividend YieldN/APrice Target$143.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Tandem Diabetes Care Stock Forecast (MarketRank)Analyst RatingModerate Buy2.78 Rating ScoreUpside/Downside131.4% Upside$143.00 Price TargetShort InterestBearish7.48% of Float Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment0.50Based on 4 Articles This WeekInsider TradingSelling Shares$1.83 M Sold Last QuarterProj. Earnings Growth194.29%From $0.35 to $1.03 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.54 out of 5 starsMedical Sector101st out of 1,429 stocksSurgical & Medical Instruments Industry10th out of 138 stocks 3.4 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $143.00, Tandem Diabetes Care has a forecasted upside of 131.4% from its current price of $61.81.Amount of Analyst CoverageTandem Diabetes Care has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.48% of the float of Tandem Diabetes Care has been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Tandem Diabetes Care has recently increased by 18.18%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Tandem Diabetes Care is -0.64. Previous Next 1.9 News and Social Media Coverage News SentimentTandem Diabetes Care has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tandem Diabetes Care this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -45% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have sold 406.33% more of their company's stock than they have bought. Specifically, they have bought $361,270.00 in company stock and sold $1,829,208.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Tandem Diabetes Care is held by insiders.Percentage Held by Institutions94.62% of the stock of Tandem Diabetes Care is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow by 194.29% in the coming year, from $0.35 to $1.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is 772.72, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 47.08.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is 772.72, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 42.02.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 9.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address About Tandem Diabetes Care (NASDAQ:TNDM)Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Read More TNDM Stock News HeadlinesJune 27, 2022 | finance.yahoo.comCVRx (CVRX) Soars 5.6%: Is Further Upside Left in the Stock?June 24, 2022 | americanbankingnews.comBrokerages Set Tandem Diabetes Care, Inc. (NASDAQ:TNDM) PT at $145.88June 24, 2022 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Rating Lowered to Sell at StockNews.comJune 23, 2022 | finance.yahoo.comTandem Diabetes Care (NASDAQ:TNDM) Might Have The Makings Of A Multi-BaggerJune 22, 2022 | finance.yahoo.comHere's Why Investors Should Retain Tandem Diabetes (TNDM) NowJune 16, 2022 | finance.yahoo.comTandem Diabetes Care Welcomes Two New Members to Board of DirectorsJune 15, 2022 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Downgraded by TheStreetJune 15, 2022 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Downgraded to D+ at TheStreetJune 12, 2022 | americanbankingnews.comTandem Diabetes Care (NASDAQ:TNDM) Sets New 52-Week Low After Insider SellingJune 12, 2022 | americanbankingnews.comDavid B. Berger Sells 10,097 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) StockJune 8, 2022 | finance.yahoo.com2 Beaten-Down Stocks With 80% to 113% Upside, According to Wall StreetJune 7, 2022 | msn.comTandem Diabetes (TNDM) Posts Positive Control-IQ Study DataJune 6, 2022 | seekingalpha.comTandem Diabetes Control-IQ Technology shows benefit in diabetic patientsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,000Year Founded2006Company Calendar Last Earnings5/04/2022Today7/01/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$143.00 High Stock Price Forecast$200.00 Low Stock Price Forecast$120.00 Forecasted Upside/Downside+131.4%Consensus RatingModerate Buy Rating Score (0-4)2.77777777777778 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$0.079990 Trailing P/E Ratio772.72 Forward P/E Ratio176.60 P/E GrowthN/ANet Income$15.57 million Net Margins0.80% Pretax Margin0.63% Return on Equity1.64% Return on Assets0.74% Debt Debt-to-Equity Ratio0.64 Current Ratio6.21 Quick Ratio5.60 Sales & Book Value Annual Sales$702.80 million Price / Sales5.63 Cash Flow$0.52 per share Price / Cash Flow118.79 Book Value$6.82 per share Price / Book9.06Miscellaneous Outstanding Shares63,963,000Free Float62,556,000Market Cap$3.95 billion OptionableOptionable Beta0.69 Social Links Tandem Diabetes Care Frequently Asked Questions Should I buy or sell Tandem Diabetes Care stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Tandem Diabetes Care stock. View analyst ratings for Tandem Diabetes Care or view top-rated stocks. What is Tandem Diabetes Care's stock price forecast for 2022? 9 Wall Street research analysts have issued 1-year price targets for Tandem Diabetes Care's stock. Their TNDM stock forecasts range from $120.00 to $200.00. On average, they anticipate Tandem Diabetes Care's stock price to reach $143.00 in the next year. This suggests a possible upside of 131.4% from the stock's current price. View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts. How has Tandem Diabetes Care's stock performed in 2022? Tandem Diabetes Care's stock was trading at $150.52 at the beginning of 2022. Since then, TNDM stock has decreased by 58.9% and is now trading at $61.81. View the best growth stocks for 2022 here. When is Tandem Diabetes Care's next earnings date? Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Tandem Diabetes Care. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) released its quarterly earnings data on Wednesday, May, 4th. The medical device company reported ($0.23) earnings per share (EPS) for the quarter. The medical device company had revenue of $175.91 million for the quarter, compared to analyst estimates of $168.21 million. Tandem Diabetes Care had a trailing twelve-month return on equity of 1.64% and a net margin of 0.80%. The company's quarterly revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.07) EPS. View Tandem Diabetes Care's earnings history. When did Tandem Diabetes Care's stock split? How did Tandem Diabetes Care's stock split work? Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850.00 million-$865.00 million, compared to the consensus revenue estimate of $846.54 million. Who are Tandem Diabetes Care's key executives? Tandem Diabetes Care's management team includes the following people: Mr. John F. Sheridan, Pres, CEO & Director (Age 67, Pay $1.6M) (LinkedIn Profile)Ms. Leigh A. Vosseller, Exec. VP, CFO & Treasurer (Age 49, Pay $764.64k) (LinkedIn Profile)Mr. David B. Berger Esq., Exec. VP & COO (Age 52, Pay $765.11k) (LinkedIn Profile)Ms. Susan M. Morrison, Exec. VP & Chief Admin. Officer (Age 43, Pay $764.35k) (LinkedIn Profile)Mr. Brian B. Hansen, Exec. VP & Chief Commercial Officer (Age 54, Pay $781.22k) (LinkedIn Profile)Ms. Elizabeth Anne Gasser, Exec. VP & Chief Strategy Officer (Age 46, Pay $764.64k) (LinkedIn Profile)Mr. Rick A. Carpenter, Chief Technical Officer (Age 59)Ms. Shannon M. Hansen, Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56)Mr. Ross Sylvia, VP of MarketingMr. Tom Fox, Sr. VP of HR & Organizational Devel. What is John Sheridan's approval rating as Tandem Diabetes Care's CEO? 11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees. Who are some of Tandem Diabetes Care's key competitors? Some companies that are related to Tandem Diabetes Care include Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Haemonetics (HAE), iRhythm Technologies (IRTC), Merit Medical Systems (MMSI) and Axonics (AXNX). View all of TNDM's competitors. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL). What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." How do I buy shares of Tandem Diabetes Care? Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $61.81. How much money does Tandem Diabetes Care make? Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.95 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or $0.079990 on an earnings per share basis. How many employees does Tandem Diabetes Care have? Tandem Diabetes Care employs 2,000 workers across the globe. When was Tandem Diabetes Care founded? Tandem Diabetes Care was founded in 2006. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for Tandem Diabetes Care is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected]. This page (NASDAQ:TNDM) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
